S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
66,000% upside on tiny biotech? (Ad)
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
66,000% upside on tiny biotech? (Ad)
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
66,000% upside on tiny biotech? (Ad)
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian markets mostly higher after Biden-McCarthy deal on US debt
PwC Australia sidelines 9 directors as leak of tax information investigated
66,000% upside on tiny biotech? (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
66,000% upside on tiny biotech? (Ad)
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
Sleepless in Kyiv: Nighttime Russian air campaign terrorizes citizens in Ukrainian capital
NASDAQ:HRMY

Harmony Biosciences (HRMY) Competitors

$35.56
-0.43 (-1.19%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$35.46
▼
$36.24
50-Day Range
$30.50
▼
$44.00
52-Week Range
$29.81
▼
$62.08
Volume
243,500 shs
Average Volume
803,171 shs
Market Capitalization
$2.13 billion
P/E Ratio
11.47
Dividend Yield
N/A
Price Target
$62.89
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

HRMY vs. BBIO, VTYX, AMPH, AKRO, VKTX, ABCL, HCM, NUVL, SLRN, and CVAC

Should you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include BridgeBio Pharma (BBIO), Ventyx Biosciences (VTYX), Amphastar Pharmaceuticals (AMPH), Akero Therapeutics (AKRO), Viking Therapeutics (VKTX), AbCellera Biologics (ABCL), HUTCHMED (HCM), Nuvalent (NUVL), Acelyrin (SLRN), and CureVac (CVAC). These companies are all part of the "pharmaceutical preparations" industry.

Harmony Biosciences vs.

BridgeBio Pharma (NASDAQ:BBIO) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking.

BridgeBio Pharma currently has a consensus price target of $26.63, indicating a potential upside of 93.64%. Harmony Biosciences has a consensus price target of $62.89, indicating a potential upside of 76.85%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Harmony Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
Harmony Biosciences
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

BridgeBio Pharma has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.

Harmony Biosciences has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$77.65 million28.42-$481.18 million-$2.84-4.84
Harmony Biosciences$437.86 million4.87$181.47 million$3.1011.47

BridgeBio Pharma received 104 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 66.49% of users gave BridgeBio Pharma an outperform vote while only 46.34% of users gave Harmony Biosciences an outperform vote.

CompanyUnderperformOutperform
BridgeBio PharmaOutperform Votes
123
66.49%
Underperform Votes
62
33.51%
Harmony BiosciencesOutperform Votes
19
46.34%
Underperform Votes
22
53.66%

Harmony Biosciences has a net margin of 40.19% compared to BridgeBio Pharma's net margin of -546.34%. Harmony Biosciences' return on equity of 49.67% beat BridgeBio Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Pharma -546.34% N/A -73.98%
Harmony Biosciences 40.19% 49.67% 28.11%

96.5% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 84.8% of Harmony Biosciences shares are held by institutional investors. 29.6% of BridgeBio Pharma shares are held by insiders. Comparatively, 28.4% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Harmony Biosciences had 1 more articles in the media than BridgeBio Pharma. MarketBeat recorded 7 mentions for Harmony Biosciences and 6 mentions for BridgeBio Pharma. Harmony Biosciences' average media sentiment score of 1.20 beat BridgeBio Pharma's score of 0.91 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Pharma
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Harmony Biosciences
3 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

BridgeBio Pharma and Harmony Biosciences tied by winning 9 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HRMY vs. The Competition

Export to Excel
MetricHarmony BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.13B$5.67B$4.39B$6.16B
Dividend YieldN/A2.72%5.94%6.15%
P/E Ratio11.479.43133.0414.49
Price / Sales4.87320.243,536.2686.88
Price / Cash10.1320.3891.70107.21
Price / Book4.815.144.997.14
Net Income$181.47M$185.80M$116.26M$192.57M
7 Day Performance-0.22%-0.74%116.16%5.72%
1 Month Performance10.30%4.15%127.49%7.33%
1 Year Performance-18.52%14.27%133.28%-0.52%

Harmony Biosciences Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBIO
BridgeBio Pharma
2.8551 of 5 stars		$13.66
-0.4%		$26.63
+94.9%		+89.9%$2.19B$77.65M-4.81576Short Interest ↓
VTYX
Ventyx Biosciences
2.0435 of 5 stars		$36.28
+2.1%		$55.40
+52.7%		+83.8%$2.12BN/A-15.9127
AMPH
Amphastar Pharmaceuticals
1.9726 of 5 stars		$43.71
-1.3%		$40.00
-8.5%		+13.6%$2.11B$498.99M24.421,615
AKRO
Akero Therapeutics
2.0264 of 5 stars		$44.34
-2.9%		$52.00
+17.3%		+406.1%$2.22BN/A-16.2433
VKTX
Viking Therapeutics
2.278 of 5 stars		$22.78
-6.4%		$30.25
+32.8%		+814.6%$2.27BN/A-23.9817
ABCL
AbCellera Biologics
2.0614 of 5 stars		$7.08
+7.1%		$25.57
+261.2%		-13.9%$2.04B$485.42M-39.33386Insider Buying
Short Interest ↑
High Trading Volume
HCM
HUTCHMED
1.5219 of 5 stars		$13.15
+0.5%		$16.00
+21.7%		+40.1%$2.28B$426.41M0.002,025Short Interest ↓
NUVL
Nuvalent
1.4699 of 5 stars		$40.37
-1.0%		$44.50
+10.2%		+326.2%$2.29BN/A-23.4740
SLRN
Acelyrin
0 of 5 stars		$21.38
+2.7%		N/AN/A$1.98BN/A0.00N/A
CVAC
CureVac
1.9793 of 5 stars		$10.46
+8.2%		$21.00
+100.8%		-52.7%$2.34B$72.33M0.001,049Short Interest ↑
Gap Up

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:HRMY) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -